Merck, Others Beat Warning Claims In Diabetes Drug MDL
By Kat Greene (November 9, 2015, 11:23 PM EST) -- Drugmakers including Merck defeated state law claims in multidistrict litigation accusing the companies of failing to warn patients of pancreas problems from Type 2 diabetes drugs when a California federal judge ruled Monday the U.S. Food and Drug Administration would have rejected the warnings on labels.
The FDA would have shot down labels by Merck , Eli Lilly & Co., Novo Nordisk Inc. and Amylin Pharmaceuticals LLC warning patients of a potential connection between several drugs used to treat diabetes and pancreatic cancer, meaning the federal agency's finding on the matter preempts state law failure-to-warn claims, U.S. District Judge Anthony J....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!